In addition, treatments that inhibit their function by targeting specific molecules such as c-Myc, CCR4-NOT2 (CNOT2), and midline1 interacting protein 1 (MID1IP1), which have recently been identified as oncogenes, have been widely proposed as novel treatments for various cancers, including colorectal cancer [6,7,8]. This evidence concerns the gene MYC and colorectal cancer.